de Monbrison Frédérique, Raynaud Delphine, Latour-Fondanaiche Christine, Staal Anne, Favre Sébastien, Kaiser Karine, Peyron François, Picot Stéphane
Laboratoire de Parasitologie, Mycologie Med.et Pathologie Exotique, Hospices Civils de Lyon, Faculté de Médecine, Université Claude Bernard, E.A. 3087, Lyon, France.
J Microbiol Methods. 2003 Sep;54(3):391-401. doi: 10.1016/s0167-7012(03)00086-1.
Plasmodium falciparum drug resistance is a major problem in malaria endemic areas. Molecular markers and in vitro tests have been developed to study and monitor drug resistance. However, none, used alone, can provide sufficient data concerning the level of drug resistance and to issue precise guidelines for drug use policies in endemic areas. We propose real-time PCR for the simultaneous detection of pfcrt and pfmdr1 genes mutations and to determine the half-maximal inhibitory response (IC(50)) of antimalarial drug. Using hybridization probes and SybrGreen technology on LightCycler instrument, point mutations of pfcrt and pfmdr1 genes have been successfully detected in 161 human blood samples and determination of IC values was applied to chloroquine-sensitive and chloroquine-resistant strains. Moreover, mixed infections caused by P. falciparum clones with wild-type or mutant alleles could be efficiency separated. The aim of this study was not to provide definitive data concerning the rate of mutations in an endemic area, but to describe a powerful method allowing the quantification of DNA for IC(50) determination and the detection of major pfmdr1 and pfcrt mutations.
恶性疟原虫耐药性是疟疾流行地区的一个主要问题。已开发出分子标记和体外试验来研究和监测耐药性。然而,单独使用任何一种方法都无法提供有关耐药水平的足够数据,也无法为流行地区的药物使用政策发布精确指南。我们提出使用实时聚合酶链反应(PCR)同时检测pfcrt和pfmdr1基因突变,并确定抗疟药物的半数最大抑制反应(IC50)。利用杂交探针和LightCycler仪器上的SybrGreen技术,已在161份人类血液样本中成功检测到pfcrt和pfmdr1基因的点突变,并将IC值测定应用于氯喹敏感株和氯喹耐药株。此外,由具有野生型或突变等位基因的恶性疟原虫克隆引起的混合感染能够被有效分离。本研究的目的不是提供有关流行地区突变率的确切数据,而是描述一种强大的方法,该方法可用于定量DNA以测定IC50,并检测主要的pfmdr1和pfcrt突变。